# OnCo record paper-marabelle-keynote-158-tmb-lancet-oncol-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-marabelle-keynote-158-tmb-lancet-oncol-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-marabelle-keynote-158-tmb-lancet-oncol-2020" ;
  schema:name "Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of KEYNOTE-158"@en ;
  schema:description "In ten hard-to-treat cancer types, 29 in 100 people whose tumours carried at least 10 mutations per million DNA letters responded to pembrolizumab, against 6 in 100 below that line."@en ;
  schema:url <https://onco.cc/key-papers/paper-marabelle-keynote-158-tmb-lancet-oncol-2020/> ;
  schema:dateModified "2026-10-20"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(20)30445-9>, <https://pubmed.ncbi.nlm.nih.gov/32919526/> ;
  onco:tag "precision" ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(20)30445-9> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Marabelle A, Fakih M, Lopez J, et al." ;
  onco:sections <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/technologies/tmb-testing/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/foundationone-cdx/> ;
  onco:terms <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/tumour-agnostic/> ;
  onco:trials <https://onco.cc/trials/keynote-158/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .